跳至主要内容
临床试验/ACTRN12612000183886
ACTRN12612000183886已完成4 期

Efficacy and safety of dihydroartemisinin-piperaquine (DP) in Pailin, Preah Vihear and Rattanakiri, and artesunate-mefloquine (ASMQ) in Preah Vihear for uncomplicated P. falciparum malaria and chloroquine (CQ) for P.vivax malaria in the above 3 sites, Cambodia, 2009

Institude Paster du Cambodge0 个研究点目标入组 420 人开始时间: 2012年2月10日最近更新:
适应症

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
420

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Non-randomised trial
主要目的
Treatment
盲法
Open (masking not used)

入排标准

年龄范围
1 Years 至 o limit(—)
性别
All

入选标准

  • Above 1 year old;
  • -Mono Infection with P. falciparum or P. vivax;
  • -Parasitaemia, 1000–200 000 asexual forms per microlitre for P.f and above 250 asexual forms per microlitre for P.v ;
  • -Axillary temperature greater than 37.5 degree C
  • -Ability to swallow oral medication;
  • -Ability and willingness to comply with the study protocol for the duration of the study and to comply with the study visit schedule;
  • -Informed consent from the patient or from a parent or guardian in case of children.

排除标准

  • -Presence of general danger signs among children <5 years old or other signs of severe and complicated falciparum malaria according to current WHO definitions;
  • -Mixed species;
  • -Presence of febrile conditions due to diseases other than malaria (measles, acute lower tract respiratory infection, severe diarrhea with dehydration, etc.),
  • -Known hypersensitivity or allergy to artesunate or mefloquine
  • -Known psychiatric disorders, e.g. depression or epilepsy
  • -Anti arrhythmic or others drugs which are known to influence cardiac function

研究者

发起方
Institude Paster du Cambodge

相似试验